Jump to:

Caprelsa: new option for advanced thyroid cancer

02 April 2012, 9:20am

Caprelsa (vandetanib) has been launched for the treatment of advanced medullary thyroid cancer (MTC) in unresectable locally advanced or metastatic disease.

Caprelsa may be less beneficial in patients with medullary thyroid carcinoma when rearranged during transfection (RET) mutation is negative or unknown | SCIENCE PHOTO LIBRARY

Caprelsa may be less beneficial in patients with medullary thyroid carcinoma when rearranged during transfection (RET) mutation is negative or unknown | SCIENCE PHOTO LIBRARY

PHARMACOLOGY

Vandetanib is a protein tyrosine kinase inhibitor that has activity against the rearranged during transfection (RET) proto-oncogene. It also acts on both vascular and epidermal growth factor receptors, resulting in reduced endothelial cell migration, proliferation and survival, and reduced blood vessel formation in in vitro models of angiogenesis. Inhibition of angiogenesis has also been observed in mice and in MTC xenograph tumours in vivo; however, the precise mechanism of action in locally advanced or metastatic MTC is unknown.1

CLINICAL STUDIES

In a double-blind study (n=331), patients with advanced MTC were randomised to receive vandetanib (300mg daily) or placebo until disease progression, determined at regular intervals by central independent assessment using the Response Evaluation Criteria in Solid Tumours (RECIST). In the event of disease progression, patients had the option to receive open-label vandetanib.2

Overall, vandetanib significantly prolonged progression-free survival to a greater extent than placebo, with an average duration in the treatment arm of 30.5 months compared with 19.3 months in the control arm (hazard ratio 0.46; 95% CI, 0.31 to 0.69; p=0.0001).2

Adverse events were reported more frequently in patients who received vandetanib than in those who received placebo, with diarrhoea, rash, nausea, hypertension and headache occurring most commonly.1,2

References:
1.    Caprelsa Summary of Product Characteristics, February 2012.
2.    Wells SA Jr et al. J Clin Oncol 2012; 10; 30: 134-41.

View Caprelsa drug record

Further information: AstraZeneca

You must log in to make full use of all the site content and features.

New users can register here free for full site access.

Related Drug Categories

 

MIMS Specialist Journals

Now available on www.mims.co.uk

Click here to view

7-Part CME IBS Programme

Irritable bowel syndrome medical education programme worth 6.5 CPD credits. Click here to view

MIMS app

Access the full MIMS database from your mobile device

Click here to find out more

MIMs Drug Search

Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.

Find drugs by:

Travel Vaccination & Malaria Advice

Travel Vaccination & Malaria Advice

Supplied by the National
Travel Health Network
and Centre (NaTHNaC)

Palliative Care Resources

Palliative Care Resources

Opioid dose conversions
and much more

Childhood Immunisation

Childhood Immunisation

Summary of routine
vaccination schedule

Referral Guidelines for Breast Disorders

Referral Guidelines for Breast Disorders

MIMS Summary of NHS Cancer Screening Referral Guidelines

Quick-reference table: antibiotics

Quick-reference table: antibiotics

Treatment regimens for common infections

Back to top